SFM
SABS icon

Sphera Funds Management’s SAB Biotherapeutics SABS Stock Holding History

Sphera Funds Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-566,395
Closed -$1.14M – 133
2025
Q3 		$1.14M Buy
+566,395
New +$1.28M 0.24% 94

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Sphera Funds Management's SABS Position: Q4 2025 in Review

Sphera Funds Management sold out of SAB Biotherapeutics (SABS) in Q4 2025, closing a stake of 566,395 shares — an estimated $1.14M sold.

Sphera Funds Management first reported a position in SABS in Q3 2025 and held it in 1 quarter. The position peaked at $1.14M in Q3 2025. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • Sphera Funds Management reported no remaining SAB Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Sphera Funds Management sold 566,395 SAB Biotherapeutics shares in Q4 2025, an estimated $1.14M.
  • Sphera Funds Management first reported a position in SAB Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • Sphera Funds Management's SAB Biotherapeutics position peaked at $1.14M in Q3 2025.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.